SS Innovations International (NASDAQ: SSII) is building a position in telerobotic surgery as remote procedures gain momentum worldwide, according to a recent MedTech Dive report. The company's founder and CEO, cardiac surgeon Dr. Sudhir Srivastava, told MedTech Dive that robotic surgery is inherently a form of teleoperation and that the central technical question is how much distance can be introduced without compromising responsiveness. The report, titled "Telerobotic surgery is advancing around the world. Will the US embrace it?," examined the technology's development and the regulatory and infrastructure questions surrounding remote surgery, highlighting SS Innovations alongside larger medical-device companies and emerging robotics developers (https://ibn.fm/4ZLvL).
As of September 28, 2026, SS Innovations reported 195 robotic telesurgeries using its SSi Mantra system, including cardiac procedures and long-distance operations. The company's installed base reached 244 SSi Mantra systems, up 45% from the end of 2025, while cumulative procedures totaled 14,503. The system has expanded into 12 countries, with recent cardiac-surgery programs launched in Colombia and Sri Lanka and a new program established at HCG Hospital in Ahmedabad. These figures indicate that telerobotic surgery is moving from isolated demonstrations toward broader clinical and regulatory development.
The implications for the medical industry are significant. Telerobotic surgery could enable specialist expertise to be delivered across long distances, potentially improving access to advanced surgical care in underserved regions. However, regulatory and infrastructure challenges remain, particularly in the United States, where the technology has yet to gain widespread adoption. SS Innovations is currently pursuing U.S. Food and Drug Administration clearance and European Union CE marking as it seeks to expand the SSi Mantra system into additional international markets. Success in these efforts could position the company to compete in a rapidly evolving surgical robotics landscape.
For investors and industry observers, SS Innovations' progress offers a window into the commercialization of telesurgery. The company's growing installed base and procedure volume suggest increasing clinical acceptance, while its regulatory pursuits could unlock larger markets. The latest news and updates relating to SSII are available in the company's newsroom at https://ibn.fm/SSII.
As telerobotic surgery continues to advance globally, the question of whether the U.S. will embrace it remains open. The outcomes of SS Innovations' regulatory applications and the broader adoption of remote surgical technologies could shape the future of surgical care delivery, with potential consequences for patients, providers, and medical-device companies alike. For more details, see the full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: https://IBN.ai/Disclaimer.
